Prothrombotic effects of angiotensin

Advances in Internal Medicine

Volumn 45, Issue , 2000, Pages 419-429

  Brown, Nancy J ^a   Vaughan, Douglas E ^b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN DERIVATIVE; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOLYTIC AGENT; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SCAVENGER; SERINE PROTEINASE INHIBITOR; SUPEROXIDE; TISSUE PLASMINOGEN ACTIVATOR;

BIOSYNTHESIS; BLOOD CLOTTING; DRUG ANTAGONISM; FIBRINOLYSIS; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECRETION; THROMBOCYTE; THROMBOSIS;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSINS; BLOOD COAGULATION; BLOOD PLATELETS; BRADYKININ; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; FREE RADICAL SCAVENGERS; HUMANS; NITRIC OXIDE; PEPTIDYL-DIPEPTIDASE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; SERINE PROTEINASE INHIBITORS; SUPEROXIDES; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0033629311     PISSN: 00652822     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Alderman MH, Madhavan S, Ooi WL, et al: Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324:1098-1104, 1991.
2. Alderman MH, Ooi WL, Cohen H, et al: Plasma renin activity: A risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 10:1-8, 1997.
3. Meade TW, Cooper JA, Peart WS: Plasma renin activity and ischemic heart disease. N Engl J Med 329:616-619, 1993.
4. Chobanian AV, Haudenschild CC, Nickerson C, et al: Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 15:327-331, 1990.
5. Chobanian AV, Haudenschild CG, Nickerson C, et al: Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension 20:473-477, 1992.
6. Aberg G, Ferrer P: Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 15:S65-S72, 1990.
7. Schuh JR, Blehm DJ, Frierdich GE, et al: Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 91:1453-1458, 1993.
8. Pfeffer MA, Braunwald E, Moye LA, et al: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial: The SAVE Investigators. N Engl J Med 327:669-677, 1992.
9. Yusuf S, Pepine CJ, Garces C, et al: Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 340:1173-1178, 1992.
10. Sealey JE, Laragh HJ: The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis, in Laragh HJ, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Treatment. New York, Raven Press, 1990, pp 1287-1317.
11. Erdos EG, Skidgel RA: The angiotensin I-converting enzyme. Lab Invest 56:345-348, 1987.
12. Timmermans PB, Chiu AT, Herblin WF, et al: Angiotensin II receptor subtypes. Am J Hypertens 5:406-410, 1992.
13. Ward PE, Russell JS, Vaghy PL: Angiotensin and bradykinin metabolism by peptidases identified in skeletal muscle. Peptides 16:1073-1078, 1995.
14. Collen D, Lijnen HR: The fibrinolytic system in man. Crit Rev Oncol Hematol 4:249-301, 1986.
15. Sprengers ED, Kluft C: Plasminogen activator inhibitors. Blood 69:381-387, 1987.
16. Loskutoff DJ, Schleef RR: Plasminogen activators and their inhibitors. Methods Enzymol 163:293-302, 1988.
17. Vaughan DE, Rouleau J-L, Ridker PM, et al: Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 96:442-447, 1997.
18. Hamsten A, Wiman B, de Faire U, et al: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313:1557-1563, 1985.
19. Hamsten A, de Faire U, Walldius G, et al: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 2:3-9, 1987.
20. Meade TW, Ruddock V, Stirling Y, et al: Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northvvick Park Heart Study. Lancet 342:1076-1079, 1993.
21. Ridker PM, Vaughan DE, Stampfer MJ, et al: Endogenous tissue-type plasminogen activator and risk of myocardial infarction [see comments]. Lancet 341:1165-1168, 1993.
22. Ridker PM, Hennekens CH, Stampfer MJ, et al: Prospective study of endogenous tissue plasminogen activator and risk of stroke [see comments]. Lancet 343:940-943, 1994.
23. Schneiderman J, Sawdey MS, Keeton MR, et al: Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A 89:6998-7002, 1992.
24. Lupu F, Bergonzelli GE, Heim DA, et al: Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 13:1090-1100, 1993.
25. Robbie LA, Booth NA, Brown AJ, et al: Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol 16:539-545, 1996.
26. Alexander CM, Werb Z: Proteinases and extracellular matrix remodeling. Curr Opin Cell Biol 1:974-982, 1989.
27. Lyons RM, Gentry LE, Purchio AF, et al: Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 110:1361-1367, 1990.
28. Padro T, Emeis JJ, Steins M, et al: Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 15:893-902, 1995.
29. Lupu F, Heim DA, Bachmann F, et al: Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 15:1444-1455, 1995.
30. Grainger DJ, Kirschenlohr HL, Metcalfe JC, et al: Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 260:1655-1658, 1993.
31. Grainger DJ, Kemp PR, Metcalfe JC, et al: The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis [see comments]. Nat Med 1:74-79, 1995.
32. Xiao Q, Danton MJ, Witte DP, et al: Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc Natl Acad Sci U S A 94:10335-10340, 1997.
33. van Leeuwen RT, Kol A, Andreotti F, et al: Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 90:362-368, 1994.
34. Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 95:995-1001, 1995.
35. Feener EP, Northrup JM, Aiello LP, et al: Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 95:1353-1362, 1995.
36. Nishimura H, Tsuji H, Masuda H, et al: Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 77:1189-1195, 1997.
37. Kerins DM, Hao Q, Vaughan DE: Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 96:2515-2520, 1995.
38. Oikawa T, Freeman M, Lo W, et al: Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 51:164-172, 1997.
39. Bouchie JL, Hansen H, Feener EP: Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells: Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol 18:1771-1779, 1998.
40. Yamashita M, Darlington DN, Weeks EJ, et al: Plasminogen activator inhibitor-1 rises after hemorrhage in rats. Am J Physiol 268:E1065-E1069, 1995.
41. Hamdan AD, Quist WC, Gagne JB, et al: Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation 93:1073-1078, 1996.
42. Pederson OD, Gram J, Bagger H, et al: Regulation of tissue-type plasminogen activator mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischemic heart disease: Possible unfavorable effects of diuretics. Coron Artery Dis 5:617-623, 1994.
43. Vaughan DE, Rouleau JL, Pfeffer MA: Role of the fibrinolytic system in preventing myocardial infarction. Eur Heart J16:31-36, 1995.
44. Brown NJ, Vaughan DE: ACE inhibition decreases PAI-1 in the setting of an activated RAS. Hypertension 30:514, 1997.
45. Ding YA, Kenyon CJ, Semple PF: Regulation of platelet receptors for angiotensin II in man. J Hypertens 3:209-212, 1985.
46. Crabos M, Bertschin S, Buhler FR, et al: Identification of AT1 receptors on human platelets and decreased angiotensin II binding in hypertension. J Hypertens 11:230S-231S, 1993.
47. Ding YA, MacIntyre DE, Kenyon CJ, et al: Potentiation of adrenaline-induced platelet aggregation by angiotensin II. Thromb Haemost 54:717-720, 1985.
48. Rajagopalan S, Kurz S, Munzel T, et al: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: Contribution to alterations of vasomotor tone. J Clin Invest 97:1916-1923, 1996.
49. Laursen JB, Rajagopalan S, Galis Z, et al: Role of superoxide in angiotensin H-induced but not catecholamine-induced hypertension [see comments]. Circulation 95:588-593, 1997.
50. Maeso R, Rodrigo E, Munozgarcia R, et al: Losartan reduces constrictor responses to endothelin-1 and the thromboxane A2 analogue in aortic rings from spontaneously hypertensive rats: Role of nitric oxide. J Hypertens 15:1677-1684, 1997.
51. Li P, Ferrario CM, Brosnihan KB: Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries. J Pharmacol Exp Ther 281:1065-1070, 1997.
52. 2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. Circulation 96:1-102, 1997.
53. Liu EC, Hedberg A, Goldenberg HJ, et al: DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2/prostaglandin H2 (TP) receptors. Prostaglandins 44:89-99, 1992.
54. 2+ mobilization and protein kinase C activation. J Clin Invest 91:547-552, 1993.
55. Smith D, Gilbert M, Owen WG: Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 66:835-839, 1985.
56. Brown NJ, Nadeau JH, Vaughan DE: Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 77:522-525, 1997.
57. Brown NJ, Gainer JV, Stein CM, et al: Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 33:1431-1435, 1999.
58. Wright RA, Flapan AD, Alberti KG, et al: Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 24:67-73, 1994.
59. Jansson JH, Boman K, Nilsson TK: Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol 44:485-488, 1993.
60. Pfeffer MA, Greaves SC, Arnold JM, et al: Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction: The Healing and Early Afterload Reducing Therapy Trial. Circulation 95:2643-2651, 1997.
61. Soejima H, Ogawa H, Yasue H, et al: Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction. Clin Cardiol 20:441-445, 1997.
62. Seljeflot I, Moan A, Kjeldsen S, et al: Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. Hypertension 27:1299-1304, 1996.